论文部分内容阅读
用１５３Ｓｍ－ＥＤＴＭＰ（ｅｔｈｙｌｅｎｅｄｉａｍｉｎｅｔｅｔｒａｍｅｔｈｙｌｅｎｅＰｈｏｓｐｈｏｎｉｃａｃｉｄ）治疗多发性骨转移癌６０例，其原发灶均经病理及细胞学证实。静脉一次给予量为１４．８～２９．６ＭＢｑ／ｋｇ体重，多数病人（５０／６０）按１８．５ＭＢｑ／ｋｇ体重计算治疗剂量，一般病人治疗１～４次，两次治疗间隔为４～８周。止痛有效率为８１．７％（４９／６０），给药前２周内９９ｍＴｃ－ＭＤＰ与给药后１５３Ｓｍ－ＥＤＴＭＰ全身骨显像进行观察比较。随访１～１２个月，认为１５３Ｓｍ－ＥＤＴＭＰ治疗多发性骨转移癌疗效好、副反应小，使用安全
153Sm-EDTMP (ethylenediaminetetramethylenephosphoric acid) was used to treat 60 cases of multiple bone metastatic carcinomas. Their primary lesions were confirmed by pathology and cytology. The once-intravenous dose was 14.8 to 29.6 MBq/kg body weight. The majority of patients (50/60) were given a therapeutic dose of 18.5 MBq/kg body weight. The average patient was treated 1 to 4 times, and the two treatment intervals were 4 to 8 week. The effective rate of analgesia was 81.7% (49/60). The 99mTc-MDP within 2 weeks before the administration and the 153Sm-EDTMP whole body bone scan after administration were observed and compared. Follow-up 1 to 12 months, 153Sm-EDTMP is considered to be effective in the treatment of multiple bone metastases, with minor side effects and safe use